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Abstract
We performed a meta-analysis with maximum individual patient data from three phase 3 trials with data
available for an elderly East Asian population to compare therapy with a pemetrexed plus platinum doublet with
other platinum-based doublets as ﬁrst-line treatment for nonsquamous nonesmall-cell lung cancer patients.
Consistent with all-age East Asians, better tumor response and tolerability supports a preference for peme-
trexed/platinum in elderly East Asians.
Background: Pemetrexed plus platinum has become a standard of care in ﬁrst-line treatment for patients with
advanced nonsquamous nonesmall-cell lung cancer. However, elderly lung cancer patients are generally under-
studied and undertreated in clinical practice in East Asia because of safety concerns. This analysis aimed to provide a
picture of the clinical beneﬁt of pemetrexed/platinum in the ﬁrst-line setting for elderly (age  65 years) East Asian
patients. Patients and Methods: Individual patient data from 3 randomized controlled phase 3 trials that enrolled East
Asian patients were analyzed in this meta-analysis. Results: In elderly East Asian patients (63 in the pemetrexed/
platinum group and 42 in the control group), pemetrexed/platinum treatment achieved more beneﬁts compared to
other platinum-based doublets, including better overall response rate (32.8% vs. 7.5%), favorable progression-free
survival (not statistically signiﬁcant in adjusted hazard ratio), and signiﬁcantly longer (3.15 vs. 1.54 months) survival
without drug-related grade 3/4 toxicity. Overall survival was numerically prolonged (16.33 vs. 13.77 months; not
statistically signiﬁcant). These beneﬁt trends were similar to those in all-age East Asian patients. In elderly East Asians,
pemetrexed/platinum treatment was also associated with a lower incidence rate of drug-related grade 3/4 adverse
events. The adverse event proﬁle was similar to that in all-age East Asians. There were no unexpected adverse events.
Conclusion: Pemetrexed/platinum had good efﬁcacy and also resulted in better overall response and tolerability than
other platinum-based doublets as ﬁrst-line treatment in nonsquamous nonesmall cell lung cancer in elderly East
Asians, which was consistent with data observed in all-age East Asians.
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First-Line Pemetrexed Plus PlatinumIntroduction
Platinum-based doublet chemotherapy has been widely studied
and is currently recommended as a standard of care in the
ﬁrst-line treatment setting for advanced-stage (IIIB and IV)
nonesmall-cell lung cancer (NSCLC) in patients with good
performance status.1 Nevertheless, there are few data about the
elderly in clinical trials. This is partially due to the compromised
physiological conditions elderly patients have, such as organ
functions, drug pharmacokinetics, and comorbidity, which are
often assumed to be medical challenges.2 In these patients, cli-
nicians worry about the potential toxicity of active treatment,
thus relying instead on monochemotherapy or best supportive
care in real-world practice.3 According to Surveillance Epidemi-
ology, and End Results (SEER) program data, from 2007 to
2011, the median age of newly diagnosed patients with lung
cancer in the United States was 70 years, and elderly ( 65 years)
patients comprised 68.5% of new cases.4 Demographics, which
are currently shifting toward an older population, suggest that
oncologists and clinicians will be seeing more elderly patients
with lung cancer in the years to come.
NSCLC histology subtype is proved to be a predictive factor of
survival after chemotherapy with pemetrexed.5 A preplanned subset
analyses of a global randomized phase 3 trial demonstrated superior
overall survival (OS) and better safety proﬁle in nonsquamous
(NSq) NSCLC patients treated with pemetrexed/cisplatin as ﬁrst-
line treatment compared to those treated with gemcitabine/
cisplatin (here referred to as the Scagliotti trial).5,6 The East Asian
subgroup analysis of the Scagliotti trial7 and a subsequent Chinese
bridging trial with an almost identical design (here referred to as the
Wu trial)8 both suggested similar efﬁcacy and a similar safety beneﬁt
of pemetrexed/cisplatin—efﬁcacy superior to that of gemcitabine/
cisplatin in East Asian patients with advanced NSq NSCLC.
Another multicenter randomized phase 3 trial with East Asian
enrollment primarily compared pemetrexed/carboplatin versus
docetaxel/carboplatin for survival without treatment-emergent grade
3/4 toxicity (SWT) (here referred to as the Rodrigues-Pereira trial).9
It also demonstrated a favorable riskebeneﬁt proﬁle of pemetrexed/
carboplatin for chemonaive patients with advanced NSq NSCLC.
Nevertheless, the data of pemetrexed plus platinum treatment for
East Asian patients from clinical trials are limited, let alone data for
elderly East Asian patients.
Meta-analysis using individual patient data (IPD) is regarded as
the reference standard for systematic review, especially when time-
to-event outcomes are evaluated.10 It extracts and then analyzes
individual-level raw data from several similar trials. We sought to
discover whether the efﬁcacy and safety data of pemetrexed/plat-
inum in elderly East Asians are consistent with those in all-age East
Asians through a meta-analysis including all available IPD data of
ﬁrst-line pemetrexed-treated East Asian patients and of elderly East
Asian patients.Materials and Methods
Selection Criteria
Phase 3 clinical trials were selected on the basis of the following
criteria: (1) randomized controlled design; (2) pemetrexed/platinum
doublet in comparison with other third-generation cytotoxic drug- Clinical Lung Cancer September 2016plus platinum doublet in the ﬁrst-line setting; (3) enrolled East
Asian patients; and (4) IPD available.
Patients
Individual data of baseline characteristics, efﬁcacy measurements,
adverse events (AE), and drug exposure were extracted from the
Lilly internal database. Key eligibility criteria for patient enrollment
in these 3 trials included NSCLC patients who were chemonaive,
had IIIB or IV disease, and had good performance status (Eastern
Cooperative Oncology Group performance status 0 or 1 in the
Scagliotti and Wu trials, 0 to 2 in the Rodrigues-Pereira trial). Only
patients with histologic or cytologic NSq NSCLC were enrolled
onto the Wu and Rodrigues-Pereira trials. Because histology was not
distinguished in the Scagliotti study design, only those NSq
NSCLC patients in the Scagliotti trial were included in this meta-
analysis. The East Asian data sets pooled for this meta-analysis
were deﬁned as patients enrolled in China, Taiwan, and Korea.
Elderly was deﬁned as age  65 years.
Chemotherapy
Enrolled patients were randomized in a 1:1 ratio to receive either
pemetrexed 500 mg/m2 þ cisplatin 75 mg/m2, or gemcitabine
1250 mg/m2 þ cisplatin 75 mg/m2 (in the Scagliotti and Wu trials),
then were randomized 1:1 to pemetrexed 500 mg/m2 þ area under
the curve (AUC) 5 carboplatin or docetaxel 75 mg/m2 þ AUC 5
carboplatin (Rodrigues-Pereira trial). Treatment regimens were
repeated every 3 weeks for a maximum of 6 cycles. Within each 21-
day cycle, patients received gemcitabine on days 1 and 8, while they
received pemetrexed, docetaxel, cisplatin, or carboplatin on day 1.
Gemcitabine/cisplatin and docetaxel/carboplatin were considered
control doublets (vs. pemetrexed/cisplatin or carboplatin) in this
analysis.
Outcome Measures
OS was measured from randomization to patient death, and
progression-free survival (PFS) was measured from randomization to
progressive disease or death. Tumor response was assessed by the
Response Evaluation Criteria in Solid Tumors version 1.0. Toxic-
ities were assessed according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0 (version 2.0 in Scagliotti trial). AE considered possibly
caused by the study drug in the opinion of the investigator were
reported as drug related. Survival without toxicity was deﬁned as the
time measured from randomization to the ﬁrst treatment-emergent
grade 3/4 AE that occurred during the study or within 30 days after
the last treatment dose or death, whichever occurred ﬁrst. OS, PFS,
and SWT were analyzed in the complete intention-to-treat popu-
lation. Overall response rate (ORR) and disease control rate (DCR)
were calculated in the tumor-response-qualiﬁed (TRQ) population.
Drug exposure and AE were studied in the safety population.
Statistical Analysis
For each single study, the hazard ratio was estimated from
multivariate Cox proportional hazard model with corresponding
covariates. The random effect model was then applied to estimate
the combined hazard ratio of time-to-event end points and the 95%
conﬁdence intervals (CI). The I2 value was provided to quantify the
Shun Lu et alheterogeneity. Median survival was estimated by the Kaplan-Meier
method based on the pooled IPD. Tumor response rate and DCR
were also estimated from the pooled data. The Fisher exact test was
applied to compare rates between treatment and control arms.
Results
Studies
Considering IPD, Lilly in-house databases were queried and
searched in 2014. Only 3 trials—that of Scagliotti et al (2008),6
Rodrigues-Pereira et al (2011),9 and Wu et al (2014)8—met the
criteria and were included.
Patient Demographic and Baseline Disease
Characteristics
A total of 437 East Asian patients (93 from the Scagliotti trial,
256 from the Wu trial, and 88 from the Rodrigues-Pereira trial)
were included in this meta-analysis as the combined intention-to-
treat population, of which 217 patients were treated with peme-
trexed/platinum and 220 with other platinum-based doublets
(Table 1). Among the East Asian population, 105 were elderly (
65 years; 63 in the pemetrexed/platinum group and 42 in the
control group). Patient demographic and baseline disease charac-
teristics for each of the 3 trials are listed in Table 1.
Drug Exposure and Dose Adjustment
In all-age East Asian patients, a median of 6 cycles was admin-
istered to both the pemetrexed/platinum and control groups (214
patients in each; safety population). The percentages of patients who
completed 4 or 6 cycles were comparable between the treatment and
control groups (Table 2). However, in elderly East Asians (63 in the
pemetrexed/platinum group and 42 in the control group), the
median number of cycles of pemetrexed/platinum treatment was
consistently 6, whereas it was only 4 cycles in the control group. In
the pemetrexed/platinum group, 58.7% of patients completed 6
cycles of therapy, while only 35.7% in the control group completed
6 cycles of therapy (Table 2). The proportion of patients with dose
reduction during the treatment was also signiﬁcantly smaller in the
pemetrexed/platinum group than in the control group (all age:
4.2% vs. 36.0%, P < .001; elderly: 7.9% vs. 33.3%, P ¼ .002)
(Table 2). Those with dose delay had similar ﬁndings (Table 2).
The percentages of mean dose (actual/planned) reﬂected dose in-
tensity achieved and were consistently over 90% in the pemetrexed/
platinum groups in all 3 trials (Supplemental Table 1 in the online
version).
Efﬁcacy
In the TRQ population of all-age East Asians (406 patients),
patients in the pemetrexed/platinum group had a signiﬁcantly higher
ORR than patients in the control group (32.9% vs. 19.6%, P ¼
.003). In elderly East Asian patients, the pemetrexed/platinum group
also showed a signiﬁcantly higher ORR than the control group
(32.8% vs. 7.5%, P ¼ .003). DCR was similar between 2 treatment
groups in both all-age and elderly East Asian patients (Table 3).
Median PFS of East Asian patients was 5.88 months in the
pemetrexed doublet group and 5.82 months in the control group
(Table 3). The adjusted hazard ratio (HR, 0.81; 95% CI, 0.56-
1.17) of PFS in East Asian patients did not show statisticalsigniﬁcance, although numerically, the pemetrexed doublet treat-
ment was favored over other platinum doublets (Figure 1). In
elderly East Asian patients, the median PFS was 6.47 months in
the pemetrexed doublet group and 6.24 months in the control
group. The adjusted HR of PFS in elderly patients was 0.73 (95%
CI, 0.37-1.42) (Table 3). The adjusted HR of PFS in East Asian
or elderly East Asian patients from each single study is plotted in
Figure 1.
The SWT of East Asian patients in the pemetrexed doublet
group (median, 5.95 months) was longer than that of the control
group (median, 1.81 months) (Table 3). The adjusted HR (0.50;
95% CI, 0.31-0.81) favored the pemetrexed doublet (Figure 2).
Furthermore, the SWT of elderly East Asian in the pemetrexed
doublet group (median, 3.15 months) was also longer than that
of the control group (median, 1.54 months), with an adjusted HR
of 0.55 (95% CI, 0.30-1.02) (Table 3). The adjusted HR values of
SWT in East Asian or elderly East Asian patients from each single
study are plotted in Figure 2.
OS of all-age East Asian patients in the pemetrexed doublet
group (median, 19.02 months) did not differ from that of the
control group (median, 16.56 months) (Table 3). The adjusted HR
was 0.99 (95% CI, 0.77-1.25). The OS of elderly East Asian did
not differ (median, 16.33 months in the pemetrexed doublet group
vs. 13.77 months in the control group; adjusted HR, 0.92; 95% CI,
0.49-1.70) (Table 3).
Adverse Events
Numbers of patients with and frequencies of drug-related
CTCAE grade 3/4 AE are listed (> 3% in either group) in
Table 4. In elderly East Asians, the most common drug-related
grade 3/4 toxicities included anemia, neutropenia, febrile neu-
tropenia, leukopenia, thrombocytopenia, vomiting, and fatigue.
Besides anemia, there was also more anorexia observed in the
pemetrexed/platinum group. The frequencies of those toxicities in
elderly patients were comparable to those in the all-age East Asian
population (Table 4). In general, elderly patients in the pemetrexed/
platinum group experienced fewer drug-related grade 3/4 laboratory
toxicities (42.9% vs. 57.1%) and fewer nonlaboratory toxicities
(9.5% vs. 16.7%) than those in the control group.
Fewer growth factors (G-CSF/GM-CSF) were used in
pemetrexed/platinum-treated elderly East Asian patients as sup-
portive therapies (pemetrexed/platinum vs. control, 9.5% vs.
26.2%). The use of other concomitant medications (analgesics,
antibiotics, and erythropoiesis-stimulating agents) were similar be-
tween the 2 groups (data not shown).
Discussion
The deﬁnition of “elderly”may vary among regulatory authorities
and clinical societies.11-13 Although debated, ages of  65 or  70
are currently 2 commonly accepted cutoffs in clinical trials. To
permit a sufﬁcient patient sample size to reach meaningful con-
clusions, we used a 65-year cutoff. On the basis of IPD data from 3
randomized controlled phase 3 trials, this meta-analysis provides
some hint of the clinical beneﬁt of pemetrexed/platinum in
elderly East Asian patients with advanced NSq NSCLC in the ﬁrst-
line setting by comparing with other platinum-based doublets.
East Asian patients enrolled onto the 3 trials included in thisClinical Lung Cancer September 2016 - e105
Table 1 Demographic and Baseline Characteristics of East Asian Patients With Advanced Nonsquamous NoneSmall-Cell Lung
Cancer
Characteristic
Scagliotti (2008)6 Wu (2014)8 Rodrigues-Pereira (2011)9 Total
Pem D
Cis
(n [ 47)
Gem D
Cis
(n [ 46)
Pem D
Cis
(n [ 126)
Gem D
Cis
(n [ 130)
Pem D
Carbo
(n [ 44)
Doc D
Carbo
(n [ 44)
Pem
Doublet
(n [ 217)
Control
(n [ 220)
Median Age 61.0 57.3 57.3 55.9 58.5 55.9 58.1 56.5
65 years, n (%) 17 (36.2) 10 (21.7) 35 (27.8) 22 (16.9) 11 (25.0) 10 (22.7) 63 (29.0) 42 (19.1)
<65 years, n (%) 30 (63.8) 36 (78.3) 91 (72.2) 108 (83.1) 33 (75.0) 34 (77.3) 154 (71.0) 178 (80.9)
Gender, %
Male 57.4 47.8 56.3 54.6 65.9 50.0 58.5 52.3
Female 42.6 52.2 43.7 45.4 34.1 50.0 41.5 47.7
Male (in 65 years) 58.8 50.0 62.9 50.0 81.8 40.0 65.1 47.6
Female (in 65 years) 41.2 50.0 37.1 50.0 18.2 60.0 34.9 52.4
ECOG PS, %
0 36.2 39.1 26.2 20.8 40.9 25.0 31.3 25.5
1 63.8 60.9 73.8 79.2 59.1 65.9 68.7 72.7
2 0 0 0 0 0 9.1 0 1.8
0 (in 65 years) 23.5 20.0 20.0 18.2 45.5 30.0 25.4 21.4
1 (in 65 years) 76.5 80.0 80.0 81.8 54.5 50.0 74.6 73.8
2 (in 65 years) 0 0 0 0 0 20.0 0 4.8
Stage, %
IIIB 25.5 13.0 15.1 15.4 9.1 27.3 16.1 17.3
IV 74.5 87.0 84.9 84.6 90.9 72.7 83.9 82.7
IIIB (in 65 years) 17.6 0 17.1 4.5 0 20.0 14.3 7.1
IV (in 65 years) 82.4 100.0 82.9 95.5 100.0 80.0 85.7 92.9
Smoking Status, %a
Never 59.6 60.9 54.8 55.4 38.6 52.3 52.5 55.9
Ever 38.3 39.1 45.2 44.6 61.4 47.7 47.0 44.1
Never (in 65 years) 47.1 70.0 45.7 63.6 9.1 50.0 39.7 61.9
Ever (in 65 years) 52.9 30.0 54.3 36.4 90.9 50.0 60.3 38.1
Abbreviations: Carbo ¼ carboplatin; Cis ¼ cisplatin; Doc ¼ docetaxel; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; Gem ¼ gemcitabine; Pem ¼ pemetrexed.
aOne patient aged < 65 years from Scagliotti study, Pem þ Cis arm, had unknown smoking status.
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characteristics (Table 1). This is likely because of the similarity of
study designs and the key inclusion/exclusion criteria used in these
trials.6,8,9
This analysis further conﬁrms that an advantage in ORR was
achieved in patients treated with pemetrexed/platinum. ORR inTable 2 Drug Exposure and Dose Adjustment
Characteristic
All-Age East Asian
Pem Doublet (n [ 214) Control (n [
No. of Cycles Completed
(Median %)
6.0 6.0
Four 78.5 72.0
Six 60.7 51.9
No. of cycles, mean 4.8 4.5
Patients with dose reduction, % 4.2 36.0
Patients with dose delay, % 75.2 71.5
Abbreviation: Pem ¼ pemetrexed.
- Clinical Lung Cancer September 2016elderly East Asian patients treated with pemetrexed/platinum
(32.8%) was close to that of the all-age East Asian patients (32.9%)
but was markedly decreased in elderly patients treated with other
doublet regimens (7.5%) compared to their all-age East Asian
counterparts (19.6%) (Table 3). Taking into consideration that
patients often obtain a clinically signiﬁcant symptomatic alleviationElderly (‡65 Years) East Asian
214) Pem Doublet (n [ 63) Control (n [ 42)
6.0 4.0
73.0 64.3
58.7 35.7
4.7 4.1
7.9 33.3
73.0 66.7
Table 3 Summary of Tumor Response and Efﬁcacy Resultsa
Patient Population
All-Age East Asian Elderly (‡65 Years) East Asian
Pemetrexed Doublet Control Pemetrexed Doublet Control
TRQ, n 207 199 61 40
ORR
% 32.9 (26.5-39.7) 19.6 (14.3-25.8) 32.8 (21.3-46.0) 7.5 (1.6-20.4)
P .003 .003
DCR
% 79.2 (73.1-84.5) 76.4 (69.9-82.1) 82.0 (70.0-90.6) 70.0 (53.5-83.4)
P .550 .225
ITT, n 217 220 63 42
PFS
Median, months 5.88 (5.55-6.47) 5.82 (5.55-6.31) 6.47 (5.03-6.87) 6.24 (5.26-7.49)
Adjusted HR 0.81 (0.56-1.17) 0.73 (0.37-1.42)
SWT
Median, months 5.95 (4.21-8.64) 1.81 (1.15-2.56) 3.15 (2.56-9.20) 1.54 (0.59-2.69)
Adjusted HR 0.50 (0.31-0.81) 0.55 (0.30-1.02)
OS
Median, months 19.02 (14.85-22.11) 16.56 (13.80-19.91) 16.33 (12.94-23.98) 13.77 (11.63-19.91)
Adjusted HR 0.99 (0.77-1.25) 0.92 (0.49-1.70)
Abbreviations: DCR ¼ disease control rate; HR ¼ hazard ratio; ITT ¼ intention to treat; ORR ¼ overall response rate; OS ¼ overall survival; PFS ¼ progression-free survival; SWT ¼ survival without
toxicity; TRQ ¼ tumor-response qualiﬁed.
aData are provided as median (95% conﬁdence interval). P values for tumor response are from Fisher exact test. Efﬁcacy outcomes are estimated from random effect model.
Shun Lu et alfrom tumor shrinkage, elderly East Asians may beneﬁt more from
pemetrexed/platinum than from other platinum-based doublet
regimens.
No statistical difference between treatments was observed in both
survival outcomes (PFS and OS), though there was some indication
in hazard ratios favoring pemetrexed/platinum over other platinum-
based doublets in all-age and elderly East Asian patients (Figure 1,
Table 3). These data showed a beneﬁt HR trend in efﬁcacy that is in
line with the results previously reported in the entire NSq popu-
lation of the Scagliotti trial: PFS, HR 0.90 (95% CI, 0.79-1.02),
and OS, HR 0.81 (95% CI, 0.70-0.94).5,6 The numerically pro-
longed median OS with pemetrexed/platinum treatment in both all-
age and elderly East Asian patients was also consistent with other
study reports.14,15 No statistical signiﬁcance between groups could
be explained. First, given that the primary end point of the
Rodrigues-Pereira trial was SWT,9 the OS data from this trial were
immature. Second, even though the maximum available IPD had
been included, the total number of patients in this meta-analysis is
still underpowered to detect any between-arm statistical difference
in OS. Additionally, given the time frame of these 3 trials, some
important factors such as EGFR mutation and ALK rearrangement
status may not had been well balanced between treatment arms for
the East Asian population in any of the 3 trials; this may be another
confounding issue for our results.
This meta-analysis further demonstrated a longer SWT with an
HR favoring pemetrexed/platinum in elderly East Asian patients as
well as all-age East Asian patients (Figure 2, Table 3). Survival
without grade 3/4 toxicity is a novel end point combining efﬁcacy
and safety outcomes. In special populations where less toxicity
would be highly preferred, such as the elderly, this is reasonableand clinically relevant. This clinical riskebeneﬁt outcome well
characterized pemetrexed-based treatment for NSq NSCLC pa-
tients. Consistent results have been previously reported by other
studies.16-18
As shown in Table 2, higher drug exposure was achieved with
pemetrexed/platinum treatment in East Asian patients, including
the elderly. In particular, elderly East Asian patients tolerated
pemetrexed/platinum better than control subjects (median number
of cycles, 6 vs. 4; dose reduction, 7.9% vs. 33.3%). This higher
drug exposure could be explained by better efﬁcacy and better
toxicity proﬁle of pemetrexed/platinum, which allowed better
treatment compliance. Pemetrexed/platinum-treated elderly East
Asians experienced lower rates of the most common grade 3/4 he-
matological AE, including neutropenia, leukopenia, lymphopenia,
thrombocytopenia, and febrile neutropenia, than those treated with
other platinum-based doublets (Table 4). Moreover, rates of vom-
iting and fatigue in pemetrexed/platinum-treated elderly East Asian
patients were also reduced. The AE proﬁle of the elderly East Asian
patients is mostly similar to that of the all-age East Asian patients,
and there was no unexpected AE in either treatment arm.
Although previous trials suggested that hematologic toxicity may
be a primary concern when treating elderly patients, recent
emerging evidence has suggested a treatment limitation in elderly
NSCLC patients that must be considered.19-23 The elderly could
still beneﬁt from chemotherapies and targeted therapies with
acceptable toxicity.3,24 A retrospective subpopulation analysis of
elderly patients mostly consisting of non-Asians in the Scagliotti trial
reported no signiﬁcant compromise by aging in terms of consistent
dose tolerance, OS beneﬁt, and safety.25 Similarly, beneﬁts of
pemetrexed/platinum were also maintained in the elderlyClinical Lung Cancer September 2016 - e107
Figure 1 Adjusted Hazard Ratios of Progression Free Survival (PFS) for All-Age East Asians (A) and Elderly East Asians (B)
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demonstrated that the toxicities of pemetrexed/platinum in elderly
East Asians were also manageable, reversible, and consistent with
favorable safety proﬁles in previous studies.15,25-27
Conclusion
There are few data regarding pemetrexed-based doublet regimens
as a ﬁrst-line standard of care from clinical trials and in the literature
about its use in elderly patients, East Asian patients, or both. To our- Clinical Lung Cancer September 2016knowledge, this is the ﬁrst IPD meta-analysis and of the largest
populations studied so far to compare pemetrexed/platinum with
other platinum-based doublets in both East Asian and elderly East
Asian patients with advanced NSq NSCLC. It showed superior
ORR and SWT as well as better tolerability of pemetrexed/platinum
than control doublets in elderly East Asian patients and in all-age
East Asians. Hence, though with a few limitations, pemetrexed/
platinum could be recommended as one of the standard-of-care
options for elderly East Asians with advanced NSq NSCLC and
Figure 2 Adjusted Hazard Ratios of Survival Without Drug-Related Grade 3/4 Toxicity for All-Age East Asians (A) and Elderly East
Asians (B)
Shun Lu et algood performance status. However, this meta-analysis is still un-
derpowered for OS difference detection in either East Asians or
elderly East Asians, and the survival data should be interpreted with
caution. Considering the heterogeneity of the elderly population
and the criteria applied in those trials, the selected population in this
analysis may not fully represent the general elderly patients in
clinical practice. Several prospective clinical trials with doublet or
monochemotherapy in elderly patients including East Asians areongoing.28-30 In the future, clinical trials in elderly patients
considering comprehensive geriatric assessment may be
warranted.31,32
Clinical Practice Points
 Pemetrexed/platinum has become a standard of care in ﬁrst-line
treatment for patients with advanced NSq NSCLC in East Asia.
However, elderly lung cancer patients are generally understudiedClinical Lung Cancer September 2016 - e109
Table 4 Most Frequent (>3% in Either Group) Drug-Related Common Terminology Criteria for Adverse Event Grade 3/4 Toxicities
Characteristic
Grade 3/4 Toxicity, n (%), for:
All-Age East Asian Elderly (‡65 Years) East Asian
Pemetrexed Doublet
(n [ 214) Control (n [ 214)
Pemetrexed Doublet
(n [ 63) Control (n [ 42)
Laboratory Toxicity
Patients with any grade 3/4
laboratory toxicities
80 (37.4) 121 (56.5) 27 (42.9) 24 (57.1)
Neutropenia 63 (29.4) 91 (42.5) 24 (38.1) 18 (42.9)
Leukopenia 12 (5.6) 57 (26.6) 7 (11.1) 15 (35.7)
Anemia 10 (4.7) 14 (6.5) 7 (11.1) 3 (7.1)
Lymphopenia 6 (2.8) 13 (6.1) 1 (1.6) 3 (7.1)
Thrombocytopenia 5 (2.3) 18 (8.4) 3 (4.8) 3 (7.1)
Febrile neutropenia 0 (0.0) 7 (3.3) 0 (0.0) 3 (7.1)
Nonlaboratory Toxicities
Patients with any grade 3/4
nonlaboratory toxicities
15 (7.0) 31 (14.5) 6 (9.5) 7 (16.7)
Vomiting 6 (2.8) 10 (4.7) 2 (3.2) 2 (4.8)
Fatigue 1 (0.5) 9 (4.2) 1 (1.6) 3 (7.1)
Anorexia 5 (2.3) 2 (0.9) 2 (3.2) 0 (0.0)
Supplemental Data
Supplemental table accompanying this article can be found in the
online version at http://dx.doi.org/10.1016/j.cllc.2016.04.003.
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e110and undertreated in clinical practice because of safety concerns
regarding the compromised physiologic conditions, such as organ
functions, drug pharmacokinetics, and comorbidity, which are
often assumed to be medical challenges.
 We performed a meta-analysis with maximum IPD from 3
randomized phase 3 trials by comparing pemetrexed/platinum
doublet with other platinum-based doublets to provide clinical
evidence of ﬁrst-line treatment for elderly East Asian advanced
NSq NSCLC patients.
 Better tumor response and tolerability, as well as a well-
characterized clinical riskebeneﬁt proﬁle of the pemetrexed/
platinum doublet, were seen compared to other platinum-based
doublets in elderly East Asian patients, and ﬁndings were
consistent with previous reports. However, survival outcome,
especially OS, is still inconclusive because of some limitations of
this analysis.
 This study supports the pemetrexed/platinum doublet as a
standard-of-care option for elderly East Asians with advanced
NSq NSCLC and good performance status.Acknowledgments
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Supplemental Table 1 Dose Intensity Achieved
Regimen
Planned Mean Dose (Actual/Planned) (%) for:
Scagliotti (2008)6 Wu (2014)8 Rodrigues-Pereira (2011)9
Pemetrexed Doublet
Pemetrexed 92.6 92.9 94.8
Cisplatin 92.6 92.6 —
Carboplatin — — 93.2
Control
Gemcitabine 83.7 91.9 —
Docetaxel — — 88
Cisplatin 87.8 92.3 —
Carboplatin — — 83.8
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